Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment

@inproceedings{Ihle2018ExpressionOC,
  title={Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment},
  author={Michaela Angelika Ihle and Sebastian Huss and Wiebke Jeske and Wolfgang Hartmann and Sabine Merkelbach-Bruse and Hans-Ulrich Schildhaus and Reinhard Buettner and Harri Sihto and Kirsten Sundby Hall and Mikael Eriksson and Peter Reichardt and Heikki Joensuu and Eva Wardelmann},
  booktitle={PloS one},
  year={2018}
}
Despite of multitude investigations no reliable prognostic immunohistochemical biomarkers in GIST have been established so far with added value to predict the recurrence risk of high risk GIST besides mitotic count, primary location and size. In this study, we analyzed the prognostic relevance of eight cell cycle and apoptosis modulators and of TP53 mutations for prognosis in GIST with high risk of recurrence prior to adjuvant treatment with imatinib. In total, 400 patients with high risk for… CONTINUE READING
1
Twitter Mention

References

Publications referenced by this paper.
SHOWING 1-10 OF 58 REFERENCES

Prognostic Relevance of p 53 Overexpression in Gastrointestinal Stromal Tumors of the Small Intestine : Potential Implication for Adjuvant Treatment with Imatinib

RM Feakins
  • Ann Surg Oncol
  • 2015

Ensembl

P Flicek, MR Amode, +3 authors S Brent
  • Nucleic Acids Res
  • 2014